Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 19-27

  Mickisch, Gerald H J ^a   Schwander, Björn ^b   Escudier, Bernard ^c   Bellmunt, Joaquim ^d   Maroto, José P ^e   Porta, Camillo ^f   Walzer, Stefan ^g   Siebert, Uwe ^h,i  

^a Center of Operative Urology Bremen   (Germany)

^b Department of Outcomes Research   (Germany)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h UNIVERSITY FOR HEALTH SCIENCES   (Austria)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bevacizumab; Indirect treatment comparison; Pazopanib; Progression free survival; Renal cell carcinoma; Sunitinib

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; INTERFERON; ISOTRETINOIN; MEDROXYPROGESTERONE ACETATE; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

AGED; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAZARD RATIO; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METASTASIS POTENTIAL; NEPHRECTOMY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 79952917182     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S16118     Document Type: Review

References (34)

1. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2004;3:CD001425.
2. Commission on Cancer, American Cancer Society. National Cancer Data Base (NCDB). 2008. Available from: http://www.facs.org/cancer/ncdb/. Accessed 2010 Dec 6.
3. Nese N, Paner GP, Mallin K, Ritchey J, Stewart A, Amin MB. Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base. Ann Diagn Pathol. 2009;13(1):1-8.
4. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin. 2007;57(2):112-125.
5. Mickisch GH. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Eur Urol. 2003;43(6):670-679.
6. Escudier B, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-alpha-2a (IFN) in metastatic renal cell carcinoma (mRCC): Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, IL, 2009 May 29-Jun 2. J Clin Oncol. 2009;27(15S):5020.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
8. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
9. Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10:54.
10. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605): 2103-2111.
11. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors: Proceedings of the American Society of Clinical Oncology(ASCO) Annual Meeting Chicago, IL, 2007 Jun 1-5. J Clin Oncol. 2007;25(18S):5024.
12. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6): 683-691.
13. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence:indirect treatment comparisons in meta-analysis. 2009; Available from: http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/884. Accessed 2010 Dec 6.
14. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003; 326(7387):472.
15. Tudur C, Williamson PR, Khan S, Best LY. The value of the aggregate data approach in meta-analysis with time-to-event outcomes. J Royal Stat Soc. 2002;164(2):357-370.
16. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet. 1999;353(9146):14-17.
17. Aass N, de Mulder PH, Mickisch GH, et al. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005;23(18): 4172-4178.
18. Mickisch GH, Garin A, van PH, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet. 2001;358(9286):966-970.
19. Snedecor GW, Cochran WG. Tests of hypotheses. In: Statistical Methods. 8th ed. Ames, IA: Iowa State University Press; 1989: 64-82.
20. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect treatment comparison software application (version 1.0). 2009. Available from: http://www.cadth.ca/index.php/en/itc-user-guide/download-software. Accessed 2010 Jul 20.
21. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol. 2008;19(8): 1470-1476.
22. Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev. 2008;2:CD006017.
23. Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer. 2009;9:34.
24. Thompson Coon JS, Liu Z, Hoyle M, et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer. 2009;101(2):238-243.
25. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422-5428.
26. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis: Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, IL, 2007 Jun 1-5. J Clin Oncol. 2007;25(18S):5010.
27. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757-763.
28. McCann L, Amit O, Pandite L, Amado R. An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC): Proceedings of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, San Francisco, CA, 2010 Mar 5-7 [Suppl; abstr # 413].
29. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010;36(1):16-23.
30. Procopio G, Verzoni E, Bajetta E, et al. Costs of managing side effects in the treatment of first line metastatic renal cell carcinoma in Italy: Bevacizumab + Interferon alpha2a compared with Sunitinib: Proceedings of the European Society for Medical Oncology (ESMO) Congress, Stockholm, Sweden, 2008 Sep 12-16. Ann Oncol. 2008; 19(8):601P.
31. Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer. 2010;102(1):80-86.
32. Bracarda S, Bellmunt J, Negrier S, et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? Experience from AVOREN: Proceedings of the European Society for Medical Oncology (ESMO) Multidisciplinary Congress, Berlin, Germany, 2009 Sep 20-24. Eur J Cancer. 2009; 7(2):P7126.
33. Melichar B. How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy? Oncology. 2009;77(2):82-91.
34. Escudier B, Goupil MG, Massard C, Fizazi K. Sequential therapy in renal cell carcinoma. Cancer. 2009;115(10 Suppl):2321-2326.